<code id='F3A81567C1'></code><style id='F3A81567C1'></style>
    • <acronym id='F3A81567C1'></acronym>
      <center id='F3A81567C1'><center id='F3A81567C1'><tfoot id='F3A81567C1'></tfoot></center><abbr id='F3A81567C1'><dir id='F3A81567C1'><tfoot id='F3A81567C1'></tfoot><noframes id='F3A81567C1'>

    • <optgroup id='F3A81567C1'><strike id='F3A81567C1'><sup id='F3A81567C1'></sup></strike><code id='F3A81567C1'></code></optgroup>
        1. <b id='F3A81567C1'><label id='F3A81567C1'><select id='F3A81567C1'><dt id='F3A81567C1'><span id='F3A81567C1'></span></dt></select></label></b><u id='F3A81567C1'></u>
          <i id='F3A81567C1'><strike id='F3A81567C1'><tt id='F3A81567C1'><pre id='F3A81567C1'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:219
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more
          Harvard's David Sinclair gets blowback over aging
          Harvard's David Sinclair gets blowback over aging

          DavidSinclairinhislabatHarvardMedicalSchool.CraigF.Walker/GlobeStaffRenownedHarvardUniversitygenetic

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          J&J to buy cancer drug developer Ambrx Biopharma

          AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki